ArticleClinical and experimental medicine2025
Development and validation of mitochondrial metabolism-related genes in the prognostic and immunological characterization of clear cell renal cell carcinoma.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MUC1/CA15-3 identifies a clear cell renal carcinoma characterized by Sunitinib response with a specific metabolic signature.Clinical and experimental medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As the most prevalent subtype of renal cell carcinoma, clear cell renal cell carcinoma (ccRCC) exhibits a tendency for metastasis and recurrence and demonstrates resistance to both radiotherapy and chemotherapy. Mitochondrial metabolism, as an important bioenergy hub, profoundly affects the tumor microenvironment. This study aims to screen potential biomarkers of ccRCC based on mitochondrial metabolism-related genes (MMRGs). Transcriptomic data for ccRCC patients were retrieved from the TCGA and ArrayExpress databases. An integrated analytical approach incorporating differential expression analysis, least absolute shrinkage and selection operator (LASSO) regression analysis, and multivariate Cox analysis was employed to identify prognostic genes associated with ccRCC. To elucidate the biological characteristics distinguishing high risk and low risk ccRCC patients, we performed GO and KEGG enrichment analyses. The ssGSEA and CIBERSORT algorithms were utilized to characterize immune cell infiltration landscapes across ccRCC patient. Furthermore, consensus clustering analysis was was applied to stratify ccRCC patients. A robust prognostic model for ccRCC was constructed based on a signature comprising six MMRGs. Significant enrichment in the Wnt signaling pathway was identified by gene enrichment analysis for differentially expressed genes that were upregulated in the high risk versus low risk group. The high risk group exhibited significantly elevated infiltration levels of T cells CD8 and regulatory T cells compared to the low risk group. Consensus clustering analysis successfully partitioned the ccRCC cohort into two molecular subtypes exhibiting significant differences in immune and molecular characteristics. The prognostic model constructed based on MMRGs can effectively predict ccRCC patients and their immune characteristics, providing a new perspective on the relationship between MMRGs and ccRCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.